Shares of Gujarat Themis Biosyn, a pharmaceutical company based in Gujarat, India, surged over 15% on April 24, 2023, following the announcement of its acquisition of 13 branded generic products from Sanofi, a French healthcare company, for €158 million (approximately ₹1,740 crore). This acquisition represents nearly 50% of Gujarat Themis Biosyn's market capitalization of ₹3,520 crore. The transaction is expected to close by the end of December 2026 and will be financed through a mix of debt and equity. The company anticipates that this deal will enhance its earnings per share (EPS) by leveraging profitable sales of branded generics and improving operational efficiency. The acquisition will provide instant access to regulated and semi-regulated markets, allowing Gujarat Themis to expand its global footprint in the anti-infective market. Analysts have noted a bullish trend for the stock, with expectations for prices to reach the ₹420–430 range, while ₹340 is seen as a strong support level.